SJEPD013_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 6.57
- e1_e2
- E2
- umap1_2d
- -6.462028404
- umap2_2d
- -0.849874745
- umap1_3d
- 0.537673806
- umap2_3d
- 2.683414859
- umap3_3d
- 1.27636951
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.510
- COAGULATION+0.470
- ANGIOGENESIS+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- IL6_JAK_STAT3_SIGNALING+0.390
- INFLAMMATORY_RESPONSE+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- XENOBIOTIC_METABOLISM+0.370
- HYPOXIA+0.320
- OXIDATIVE_PHOSPHORYLATION+0.310
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.440
- MITOTIC_SPINDLE-0.410
- MYC_TARGETS_V2-0.400
- PI3K_AKT_MTOR_SIGNALING-0.140
- UV_RESPONSE_DN-0.130
- WNT_BETA_CATENIN_SIGNALING-0.090
- MTORC1_SIGNALING-0.060
- UNFOLDED_PROTEIN_RESPONSE-0.060
- APICAL_JUNCTION-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0410 | Med | Medulloblastoma | 0.896 |
| 2 | BS_C51RB0YR | low-grade glioma | — | 0.891 |
| 3 | cc158c27-a2f0-4403-ae01-913bfcc623cc | — | — | 0.889 |
| 4 | TCGA-A7-A3IY-01A-21R-A21T-07 | — | C | 0.888 |
| 5 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.885 |
| 6 | SRR1331597 | GTEX | — | 0.883 |
| 7 | SRR663693 | GTEX | — | 0.880 |
| 8 | SRR33532823 | — | C | 0.877 |
| 9 | sclc2388_S39.txt | — | cohortMD2 | 0.875 |
| 10 | MDT-AP-2021 | Med | Medulloblastoma | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| COAGULATION | 0.470 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |